Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Theolytics Doses First Patient In Phase I Iia Trial Of Theo 260 In Ovarian Cancer is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in ...
Theolytics CSO and Co-Founder Margaret Duffy PhD, added “Enrolling the first patient into our Phase I/IIa trial for THEO-260 marks a major milestone for Theolytics. As a team, we seek to deliver ... Read More
Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in ...
Theolytics. THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in advanced ovarian cancer and other solid tumours. Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus